Therapy Areas: AIDS & HIV
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine
29 March 2022 - - Singapore-based biopharmaceutical company Prestige Biopharma Ltd. and Australian biotechnology company Vaxine Pty Ltd have entered into a memorandum of understanding to collaborate on the supply of Vaxine's COVID-19 Vaccine, Covax-19 (also known as Spikogen) and on the co-development of COVID-19/influenza combo vaccine, the principals said.

Vaxine has developed a recombinant protein vaccine against COVID-19 that is manufactured using insect cells and includes Vaxine's proprietary Advax polysaccharide adjuvant.

This vaccine showed efficacy against infection by the Delta variant in Phase 3 clinical trials and already is in use in the Middle East.

In December 2021, the Australian Therapeutic Goods Administration granted a provisional determination allowing an application to be lodged for a provisional approval for this COVID-19 vaccine.

Regulatory submissions are similarly underway in many other countries in parallel.

Industry experts remain concerned that the next pandemic might be even worse than Covid-19, creating an urgent need to develop strong and affordable pandemic vaccine platforms like the one Vaxine created for its Covid-19 and influenza pandemic vaccine production.

Through this MOU, Prestige and Vaxine will be building a long-term vaccine partnership, initially focused on manufacturing and commercialization of Vaxine's Covid-19 vaccine and then as Covid-19 enters an endemic phase development of a next generation Covid-19/influenza combo vaccine as well as other vaccine projects.

The MOU will bring together Prestige's global scale vaccine manufacturing capacity and research expertise with Vaxine's innovative vaccine technologies including its vaccines against COVID-19, seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, dengue, malaria, allergy and cancer.

Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company with operations in USA and Korea, specializing in the discovery and development of biosimilars, novel antibodies and vaccines.

Prestige said it strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-Ulenistamab) that recently obtained orphan designation from FDA, EMA and MFDS.

The company's portfolio of biosimilars in various stages include HD201 trastuzumab in EU EMA's MAA review, HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others.

Prestige has expanded its business into development and manufacturing of vaccines through its global scale vaccine center, starting with partnered commercial production of COVID-19 vaccines.

Vaxine is an Australian biotechnology company specializing in the research and development of novel vaccines and drugs against pathogens that pose major public health or biodefense threats.

The company was founded in 2002 by Professor Nikolai Petrovsky, a world leading vaccine expert based at Flinders University in Adelaide, South Australia.

Vaxine has received extensive funding support from the US government for its pandemic vaccine development programs and has worked extensively with U.S army researchers to develop vaccines against a range of exotic pathogens including Ebola, dengue, Covid-19, malaria, MERS and Hantaan hemorrhagic fever.

More recently, it has seen success with its allergy and cancer vaccine programs. At the center of Vaxine's technological prowess lies Advax, one of the first major breakthroughs in vaccine adjuvants in almost a hundred years.


Related Headlines